复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床研究

Clinical study of compound Biejiaruangan tablets combined with entecavir in treatment of chronic hepatitis with hepatic fibrosis

目的:探讨临床使用复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化患者的疗效。方法:收治慢性乙型肝炎肝纤维化患者102例,随机平分两组。对照组实施恩替卡韦进行治疗,试验组实施复方鳖甲软肝片联合恩替卡韦进行治疗,对比两组患者治疗前后的肝功能、肝纤维化指标,治疗过程中的不良反应发生率。结果:治疗后的结果较治疗前相比较,两组患者的肝功能都有显著的恢复(P<0.05);两组患者的肝纤维化指标都有显著降低,而且试验组的各指标水平较对照组而言,显著降低(P<0.05)。结论:对于慢性乙型肝炎肝纤维化患者,临床使用复方鳖甲软肝片联合恩替卡韦治疗,效果良好,而且安全性高,有助于改善肝功能以及肝纤维化程度。

Objective：To investigate the efficacy of compound Biejiaruangan tablets combined with entecavir in treatment of chronic hepatitis with hepatic fibrosis.Methods：102 cases of chronic hepatitis with hepatic fibrosis were selected.They were randomly divided into the two groups on average.The control group was treated with entecavir for treatment,while the test group received Biejiaruangan tablets combined with entecavir treatment.The liver function,liver fibrosis index and incidence of adverse reactions in the two groups before and after treatment were compared.Results：After treatment,the liver function of the two groups had significant recovery compared with that before treatment（P〈0.05）.The indexes of liver fibrosis in the two groups were significantly reduced,and the indexes in the experimental group were significantly lower than those in the control group（P〈0.05）.Conclusions：For patients with chronic hepatitis B with liver fibrosis,the clinical use of compound Biejiaruangan tablets combined with entecavir has good effect and safety,which can help to improve the liver function and the degree of liver fibrosis.